Nuvectis Pharma (NVCT) Expected to Announce Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) is projected to announce its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 7:00 AM ET.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Wednesday, February 11th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.05). On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Stock Performance

Shares of NASDAQ:NVCT opened at $8.46 on Monday. Nuvectis Pharma has a 52 week low of $5.55 and a 52 week high of $11.52. The firm has a market cap of $224.11 million, a PE ratio of -6.41 and a beta of -0.30. The firm’s fifty day moving average is $8.32 and its 200-day moving average is $7.00.

Wall Street Analysts Forecast Growth

A number of research firms have commented on NVCT. HC Wainwright reiterated a “buy” rating on shares of Nuvectis Pharma in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuvectis Pharma in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Nuvectis Pharma currently has an average rating of “Moderate Buy” and an average target price of $15.33.

Institutional Investors Weigh In On Nuvectis Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Nuvectis Pharma by 4.8% in the third quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock worth $4,206,000 after purchasing an additional 31,903 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Nuvectis Pharma by 11.8% during the 4th quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock worth $2,749,000 after buying an additional 38,291 shares during the period. State Street Corp increased its stake in shares of Nuvectis Pharma by 13.1% in the 4th quarter. State Street Corp now owns 154,666 shares of the company’s stock valued at $1,168,000 after acquiring an additional 17,950 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Nuvectis Pharma by 63.6% in the 2nd quarter. Marshall Wace LLP now owns 63,613 shares of the company’s stock valued at $475,000 after acquiring an additional 24,739 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Nuvectis Pharma during the 1st quarter valued at $446,000. Institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.